AUTHOREA
Log in Sign Up Browse Preprints

loading page

COMPLEMENT INHIBITOR ECULIZUMAB IN ATYPICAL HEMOLYTIC-UREMIC SYNDROME: SINGLE CENTER CASE SERIES
  • +4
  • Monika Vitkauskaitė,
  • Artūras Vinikovas,
  • Marius Miglinas,
  • Laurynas Rimševičius,
  • Agnė Čerkauskaitė,
  • Ernesta Mačionienė,
  • Eglė Ašakienė
Monika Vitkauskaitė
Vilniaus universitetas Medicinos fakultetas

Corresponding Author:[email protected]

Author Profile
Artūras Vinikovas
Vilniaus universitetas Medicinos fakultetas
Author Profile
Marius Miglinas
Vilniaus universitetas Medicinos fakultetas
Author Profile
Laurynas Rimševičius
Vilniaus universitetas Medicinos fakultetas
Author Profile
Agnė Čerkauskaitė
Vilniaus universitetas Medicinos fakultetas
Author Profile
Ernesta Mačionienė
Vilniaus universitetas Medicinos fakultetas
Author Profile
Eglė Ašakienė
Vilniaus universitetas Medicinos fakultetas
Author Profile

Abstract

Our case series showed that eculizumab is efficacious and safe in treating atypical hemolytic-uremic syndrome, as well as it has positive effects on quality of life. Further extensive studies are required to develop unified treatment guidelines.

Peer review status:ACCEPTED

24 Sep 2021Submitted to Clinical Case Reports
Show details
Hide details
25 Sep 2021Submission Checks Completed
25 Sep 2021Assigned to Editor
04 Oct 2021Reviewer(s) Assigned
17 Nov 2021Review(s) Completed, Editorial Evaluation Pending
17 Nov 2021Editorial Decision: Revise Minor
16 Jan 20221st Revision Received
17 Jan 2022Submission Checks Completed
17 Jan 2022Assigned to Editor
17 Jan 2022Review(s) Completed, Editorial Evaluation Pending
16 Feb 2022Editorial Decision: Accept